Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publications 2018

Original Papers

  • Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL,Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP,Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A,Farsaci B, Ansell SM. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018 May 10;36(14):1428-1439. Epub 2018 Mar 27.
  • Baues C, Marnitz S, Engert A, Baus W, Jablonska K, Fogliata A, Vásquez-Torres A, Scorsetti M, Cozzi L. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : A planning comparison of deep inspiration breath hold intensity modulation radiotherapy and intensity modulated proton therapy. Radiat Oncol. 2018 Jul 3; 13(1):122.
  • Böll B, Plütschow A, Bürkle C, Atta J, Pfreundschuh M, Feuring-Buske M, Vogelhuber M, Sökler M, Eichenauer DA, Thielen I, von Tresckow B, Fuchs M, Engert A, Borchmann P. Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. Br J Haematol. 2018 Dec 28. [Epub ahead of print].
  • Borchmann S, Müller H, Haverkamp H, Baues C, Marková J, Hüttmann A, Glunz A, Fuchs M, Borchmann P, Engert A. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG). Leukemia. 2019 Feb; 33(2):439-446. Epub 2018 Aug 21.
  • Borchmann S, Engert A. Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma. Oncotarget. 2018 Dec 25; 9(101):37462-37463. eCollection 2018 Dec 25.
  • Hude I, Sasse S, Bröckelmann PJ, Tresckow  B, Momotow  J, Engert A, Borchmann S. Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition. Br J Haematol. 2018 Jun;181(6):837-840. Epub 2017 Apr 25.
  • Kobe C, Goergen H, Baues C, Kuhnert G, Voltin CA, Zijlstra J,Hoekstra O, Mettler J, Drzezga A, Engert A, Borchmann P, Dietlein  M. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. Blood. 2018 Nov 22;132(21):2273-2279. Epub 2018 Aug 30.
  • Kreissl S, Goergen H, Müller H, Meissner J, Mehnert A, Bürkle C, Fuchs M, Engert A, Behringer K, Borchmann P. Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group. Leuk Lymphoma. 2018 Dec 3:1-10. [Epub ahead of print]
  • Mettler J, Müller H, Voltin CA, Baues C, Klaeser B, Moccia A, Borchmann P, Engert A, Kuhnert G, Drzezga AE, Dietlein M, Kobe C. Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma. J Nucl Med. 2018 Jun 7. pii: jnumed.118.210047. [Epub ahead of print].
  • Sasse S, Goergen H, Plütschow A, Böll B, Eichenauer DA, Fuchs M, Behringer K, Zijlstra JM, Greil R, Markova J, Topp MS, Meissner J, Neubauer A, Baues C, Engert A, Borchmann P, von Tresckow B. Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. J Clin Oncol. 2018 Sep 1; 36(25):2603-2611. Epub 2018 Jul 10.
  • Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S,Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann Oncol. 2018 Sep 1; 29(9):1926-1931.
  • Voltin CA, Mettler J, Boellaard R, Kuhnert G, Dietlein M, Borchmann P, Drzezga A, Kobe C. Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma: is it significantly affected by contrast-enhanced computed tomography attenuation correction? Nucl Med Commun. 2018 Nov 19. [Epub ahead of print].
  • von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C,Baues C, Diehl V, Engert A, Borchmann P. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct; 5(10):e462-e473.

Reviews

  • Borchmann S, Engert A, Böll B. Hodgkin lymphoma in elderly patients. Curr Opin Oncol. 2018 Sep; 30(5):308-316.
  • Bröckelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood. 2018 Apr 12;131(15):1666-1678. Epub 2018 Mar 2. DOI: 10.1182/blood-2017-10-772665.
  • Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).Cochrane Database Syst Rev. 2018 Jul 12;7:CD012556.